Garima Sharma։ The 1st International Consensus on GLP-1RAs Across Women’s Reproductive Life Course
Garima Sharma, Director of Women’s Cardiovascular Health at Inova Health System, shared a post on LinkedIn about a paper by Sarah Dib et al. published in The Lancet Obstetrics, Gynaecology, and Women’s Health:
“The first international consensus recommendations from The Lancet Group on the use of GLP-1 receptor agonists across the reproductive life course in women with diabetes were developed by integrating a systematic review and meta-analysis of more than 43 000 women exposed to GLP-1 receptor agonists, expert consensus from 42 specialists with international representation, and input from 60 women with lived experience.
Available evidence, predominantly in women with type 2 diabetes, suggests that there is no increase in congenital anomaly risk following first-trimester discontinuation of GLP-1 receptor agonists, compared with no GLP-1 receptor agonist exposure, but important uncertainties remain regarding pregnancy loss, pregnancy exposure beyond the first trimester, and postpartum use.
The consensus panel supported GLP-1 receptor agonist use for preconception metabolic optimisation where needed in women with type 2 diabetes and recognised potential benefits in women with type 1 diabetes and previous gestational diabetes, although direct evidence in these groups is scarce.
The consensus recommendations should be interpreted in the context of little direct evidence and low certainty. Future studies focused on fertility, breastfeeding, and lactation impact, etc are needed.”
Title: Preconception, pregnancy, and postnatal use of GLP-1 receptor agonist-based therapies in women with type 1, type 2, or gestational diabetes: a systematic review, meta-analysis, and international expert consensus statement.
Authors: Sarah Dib, Matthew J Savage, Dawn Adams, Melanie J Davies, Rita Forde, Angela C Flynn, Paul W Franks, Alison Harte, Ritwika Mallik, Susan E Ozanne, Caroline Ovadia, Dimitris Papamargaritis, Rebecca M Reynolds, Naveed Sattar, Sara G I Suliman, Tricia Tan, Jovanna Tsoutsouki, Georgia Weston, Sara L White, Claire L Meek, on behalf of the GLP-1 Receptor Agonist Diabetes in Pregnancy Consensus Group.
You can read the Full Article in The Lancet Obstetrics, Gynaecology, and Women’s Health.
Stay informed with the latest updates in fertility and reproductive medicine on Fertility News.
-
Oct 3, 2026, 18:27Non-Invasive Prenatal Testing: Science, Counselling, Global Access and Equity – IJGO
-
Oct 3, 2026, 18:19Erica Marsh: Congratulations to the 4 Doctors Who Were Named 2026 Top Docs by Hour Detroit Magazine
-
Oct 3, 2026, 18:16Shizuko Takahashi: What about the “Biological Clock” in Men?
-
Oct 3, 2026, 18:11Devyanshi Dixit: Call for Speakers for GFWH 2026
-
Oct 3, 2026, 18:06Shaun Greenaway: The More We Understand Male Fertility, the Better Decisions We Can Make
-
Oct 3, 2026, 17:55Reproductive BioMedicine Online’s Latest Issue, 53.4, Is Out
-
Oct 3, 2026, 17:50Ananya Anand Kumar: Excited to Share that My Cryopreservation Abstract Was Accepted for Fertility 2027
-
Oct 3, 2026, 17:48Pregnancy of the Future: Predicting, Preventing, and Treating the Great Obstetric Syndromes – SMFM
-
Oct 3, 2026, 17:46PMOS Was Never Just About the Ovaries… – PCOS Awareness Association